Abstract

This book presents original results on the leading edge of cancer research. Chapter One provides a comprehensive discussion to address the potential benefits of myricetin on cancer, diabetes, and neurodegenerative disease. It also discusses the underlined mechanism involved in the biological action of myricetin. Chapter Two discusses the clinical significance of vasculogenic mimicry. Chapter Three studies bacterial toxins as a direct cause of cancer. Chapter Four examines the immunological aspect of stroma in ovarian cancer. Chapter Five focuses on immune checkpoint inhibitors in the treatment of solid tumors. Chapter Six provides a review of targeting non-coding mitochondrial RNAs in gynecological and urinary malignancies. Chapter Seven explores the NF-κB signaling pathway, and its targeting in human cancer treatment. Chapter Eight analyzes the circadian rhythm and skin cancer prevention. The final section of this book is a short commentary on melanoma. (Imprint: Nova Biomedical)